🇺🇸 FDA

P1 · Therapeutic area intelligence

Obesity & metabolic patent intelligence

GLP-1, GIP/GLP-1, diabetes, and metabolic disease patents — critical for obesity market IP tracking.

Patents
276

Quick answer

276 US pharmaceutical patents in our index match Obesity & metabolic title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 8334282

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8318666

    Use of leptin to treat metabolic abnormalities associated with lipoatrophy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8309525

    Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof

    The Regents of the University of California · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8293869

    Polymer conjugates of GLP-1

    Nektar Therapeutics · Granted Tue Oct 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8278272

    GLP-1, exendin-4, peptide analogs and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 02 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8263759

    Sets of probes and primers for the diagnosis of select cancers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8263662

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8236821

    Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Aug 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8217038

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Jul 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8158677

    Treatment of viral infections by modulation of host cell metabolic pathways

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8138216

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8133904

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8129341

    Methods for treating diabetic wounds

    CALREGEN INC. · Granted Tue Mar 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8124802

    MAO inhibiting N-benzyl-N-propargyl-amines useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8101740

    Positron emission tomography probes for imaging immune activation and selected cancers

    The Regents of the University of California · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8088926

    Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8088798

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jensen Discovery, Inc. · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8088809

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8084016

    Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products

    The Regents of the University of California · Granted Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8067416

    Methods and compositions for the treatment of metabolic disorders

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7998928

    Method of treatment of type-1 diabetes with a humanin analogue

    The Regents of the University of California · Granted Tue Aug 16 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7998968

    Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 16 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7994226

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7994143

    Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates

    The Regents of the University of California · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7956220

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Jun 07 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7932289

    Remedy for diabetes

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 26 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7906482

    Anti-obesity agents

    Advanced Diagnostics and Discovery · Granted Tue Mar 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7888116

    Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Feb 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7879909

    Use of Treprostinil to treat neuropathic diabetic foot ulcers

    United Therapeutics Corporation · Granted Tue Feb 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7803940

    Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 28 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7759335

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrm Discovery, Inc. · Granted Tue Jul 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7749983

    Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates

    The Regents of the University of California · Granted Tue Jul 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7718386

    Methods for the diagnosis of diabetes

    The Regents of the University of California · Granted Tue May 18 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7687481

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Mar 30 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7666889

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Feb 23 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7662780

    Administering hypocretin to obese individuals

    The Regents of the University of California · Granted Tue Feb 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7655685

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Feb 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7651845

    Method and apparatus for glucose control and insulin dosing for diabetics

    The Regents of the University of California · Granted Tue Jan 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7651707

    Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome

    The Regents of the University of California · Granted Tue Jan 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7649115

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Jan 19 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7576050

    GLP-1 exendin-4 peptide analogs and uses thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Aug 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7566714

    Methods and compositions for the treatment of metabolic disorders

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Jul 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7557081

    Alpha-1-acid glycoprotein for the treatment of diabetes

    Essential Skincare, LLC · Granted Tue Jul 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7482470

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7449171

    Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products

    The Regents of the University of California · Granted Tue Nov 11 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7378095

    Methods of treating type I diabetes by blocking VEGF-mediated activity

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7358086

    Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

    The Regents of the University of California · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7329401

    Cyclooxygenase-2 selective agents useful as imaging probes and related methods

    The Regents of the University of California · Granted Tue Feb 12 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Obesity & metabolic patents are indexed?

276 patents match our Obesity & metabolic classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.